Other Consolidated Financial Statement Detail (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash paid during the year for:
Interest	$ 66,700,000	$ 68,100,000	$ 68,100,000
Income taxes	332,700,000	394,700,000	745,400,000
Other income (expense), net
Interest income	19,200,000	22,300,000	48,500,000
Interest expense	(33,000,000)	(36,100,000)	(35,800,000)
Impairments of investments	(11,500,000)	(21,300,000)	(10,600,000)
Gain (loss) on sales of investments, net	17,400,000	16,300,000	22,800,000
Foreign exchange gains (losses), net	(6,300,000)	(3,500,000)	11,400,000
Other, net	700,000	3,300,000	1,000,000
Total other income (expense), net	(13,477,000)	(18,983,000)	37,252,000
Other current assets
Deferred tax assets	8,100,000	112,200,000
Derivative assets	39,500,000	1,300,000
Prepaid taxes	15,200,000	31,400,000
Receivable from collaborations	11,400,000	7,300,000
Interest receivable	6,500,000	4,900,000
Other prepaid expenses	45,500,000	47,900,000
Other	18,400,000	10,800,000
Total other current assets	144,600,000	215,822,000
Accrued Expenses and Other
Employee compensation and benefits	176,300,000	159,700,000
Revenue-related rebates	115,000,000	105,300,000
Deferred revenue	69,600,000	41,300,000
Royalties and licensing fees	47,400,000	45,100,000
Collaboration expenses	44,200,000	31,600,000
Clinical development expenses	40,800,000	24,400,000
Construction in progress accrual	22,800,000	16,400,000
Interest payable	21,600,000	21,600,000
Current portion of contingent consideration	(10,800,000)	(11,900,000)
Restructuring charges	1,400,000	66,400,000
Derivative liabilities	500,000	12,200,000
Other	126,800,000	130,000,000
Total accrued expenses and other	$ 677,210,000	$ 665,923,000